India Server
AddThis Feed Button
SpectrumSpectrum

Spectrum
The generic versions of Astrazeneca's anti-ulcer drug, Prilosec 40 mg will be launched by Ranbaxy Laboratories Limited in the US.


Ranbaxy Laboratories Limited Launches Generic Anti-Ulcer Drug Prilosec 40 MG
Last Updated: 2008-07-29T10:13:10+05:30
PrintMailRecommend This Site

The generic versions of the Anglo-Swedish pharmaceutical company, Astrazeneca’s anti-ulcer drug Prilosec 40 mg will be introduced by India’s Ranbaxy Laboratories Limited in the United States. The Anglo-Swedish pharmaceutical company made Ranbaxy a legal generics partner following an agreement in April.

 

This connotes that the India’s largest pharmaceutical company Ranbaxy can market its generic drugs for 180 days prior the patent expiry of Prilosec. Watson Pharma of United States, however, which was the very first generic company to effectively challenge the patent of Prilosec, will also have exclusive marketing rights during the 180 day period.

 

A statement issued by the Ranbaxy Company stated that as per the IMS figures, the yearly sale of Prilosec 40 mg in the United States is about $204 million. Ranbaxy’s shares at the BSE closed at Rs 494.20, up 2.6% from Friday’s close.

More news on:   • International Business   • Ranbaxy  

PrintMailRecommend This Site


Business


Top 


Latest News


More topics in Business